Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine.

The amino acid pairing peptide EAK16-II (EAK) has shown the ability to stabilize the hydrophobic anticancer agent ellipticine (EPT) in aqueous solution. In this study, we investigate pharmacokinetics of the formulation of EAK-EPT complexes in vivo. The developed formulation can achieve a sufficientl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Weina Ma, Sheng Lu, Pei Pan, Parisa Sadatmousavi, Yongfang Yuan, P Chen
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/901a78d2e79b4836aef95c36ab56a322
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:901a78d2e79b4836aef95c36ab56a322
record_format	dspace
spelling	oai:doaj.org-article:901a78d2e79b4836aef95c36ab56a3222021-11-18T07:06:55ZPharmacokinetics of peptide mediated delivery of anticancer drug ellipticine.1932-620310.1371/journal.pone.0043684https://doaj.org/article/901a78d2e79b4836aef95c36ab56a3222012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22952737/?tool=EBIhttps://doaj.org/toc/1932-6203The amino acid pairing peptide EAK16-II (EAK) has shown the ability to stabilize the hydrophobic anticancer agent ellipticine (EPT) in aqueous solution. In this study, we investigate pharmacokinetics of the formulation of EAK-EPT complexes in vivo. The developed formulation can achieve a sufficiently high drug concentration required in vivo animal models. The nanostructure and surface properties of EAK-EPT complexes or nanoparticle were characterized by transmission electron microscopy (TEM) and zeta potential measurements, respectively. 12 healthy male SD rats were divided into EPT group and EAK-EPT group randomly. Rats in EPT group were tail intravenously injected with the EPT (20 mg/kg); rats in EAK-EPT group were injected with EAK-EPT complexes (EPT's concentration is 20 mg/kg). EPT was extracted from rat plasma with dexamethasone sodium phosphate as internal standards (IS). The pharmacokinetic parameters were obtained using high pressure liquid chromatography (HPLC). Significant differences in main pharmacokinetic parameters between EPT and EAK-EPT complexes were observed, demonstrating that the complexation with EAK prolongs the residence time of the drug and enlarges the area under the concentration-time curve (AUC). This means that EAK can serve as a suitable carrier to increase the bioavailability of EPT.Weina MaSheng LuPei PanParisa SadatmousaviYongfang YuanP ChenPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 8, p e43684 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Weina Ma Sheng Lu Pei Pan Parisa Sadatmousavi Yongfang Yuan P Chen Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine.
description	The amino acid pairing peptide EAK16-II (EAK) has shown the ability to stabilize the hydrophobic anticancer agent ellipticine (EPT) in aqueous solution. In this study, we investigate pharmacokinetics of the formulation of EAK-EPT complexes in vivo. The developed formulation can achieve a sufficiently high drug concentration required in vivo animal models. The nanostructure and surface properties of EAK-EPT complexes or nanoparticle were characterized by transmission electron microscopy (TEM) and zeta potential measurements, respectively. 12 healthy male SD rats were divided into EPT group and EAK-EPT group randomly. Rats in EPT group were tail intravenously injected with the EPT (20 mg/kg); rats in EAK-EPT group were injected with EAK-EPT complexes (EPT's concentration is 20 mg/kg). EPT was extracted from rat plasma with dexamethasone sodium phosphate as internal standards (IS). The pharmacokinetic parameters were obtained using high pressure liquid chromatography (HPLC). Significant differences in main pharmacokinetic parameters between EPT and EAK-EPT complexes were observed, demonstrating that the complexation with EAK prolongs the residence time of the drug and enlarges the area under the concentration-time curve (AUC). This means that EAK can serve as a suitable carrier to increase the bioavailability of EPT.
format	article
author	Weina Ma Sheng Lu Pei Pan Parisa Sadatmousavi Yongfang Yuan P Chen
author_facet	Weina Ma Sheng Lu Pei Pan Parisa Sadatmousavi Yongfang Yuan P Chen
author_sort	Weina Ma
title	Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine.
title_short	Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine.
title_full	Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine.
title_fullStr	Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine.
title_full_unstemmed	Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine.
title_sort	pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/901a78d2e79b4836aef95c36ab56a322
work_keys_str_mv	AT weinama pharmacokineticsofpeptidemediateddeliveryofanticancerdrugellipticine AT shenglu pharmacokineticsofpeptidemediateddeliveryofanticancerdrugellipticine AT peipan pharmacokineticsofpeptidemediateddeliveryofanticancerdrugellipticine AT parisasadatmousavi pharmacokineticsofpeptidemediateddeliveryofanticancerdrugellipticine AT yongfangyuan pharmacokineticsofpeptidemediateddeliveryofanticancerdrugellipticine AT pchen pharmacokineticsofpeptidemediateddeliveryofanticancerdrugellipticine
_version_	1718423928356995072

Pharmacokinetics of peptide mediated delivery of anticancer drug ellipticine.

Ejemplares similares